A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (NCT06388564)

🧪 Interventions in This Study

• Axatilimab (DRUG)
• Ruxolitinib (DRUG)
• Corticosteroids (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (68 Sites)

Showing the first 25 of 68 sites.

• Mayo Clinic Hospital — Phoenix, Arizona
• City of Hope Medical Center — Duarte, California
• University of California-Los Angeles Medl Cntr-Oncology Center Bowyer Clinic — Los Angeles, California
• Stanford Cancer Center — Stanford, California
• University of Colorado Cancer Center — Aurora, Colorado
• Colorado Blood Cancer Institute — Denver, Colorado
• Smilow Cancer Center-Yale — New Haven, Connecticut
• Mayo Clinic Jacksonville — Jacksonville, Florida
• Northwestern University — Chicago, Illinois
• The University of Chicago Medicine — Chicago, Illinois
• University of Maryland-Greenebaum Cancer Center — Baltimore, Maryland
• Washington University — St Louis, Missouri
• Fred and Pamela Buffett Cancer Center — Omaha, Nebraska
• Memorial Sloan Kettering Cancer Center — New York, New York
• Weill Cornell Medicine — New York, New York
• Mount Sinai Hospital — New York, New York
• Cleveland Clinic — Cleveland, Ohio
• The Ohio State University — Columbus, Ohio
• University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania
• Hillman Cancer Center — Pittsburgh, Pennsylvania
• Vanderbilt University Medical Center — Nashville, Tennessee
• Md Anderson Cancer Center — Houston, Texas
• Fred Hutchinson Cancer Center — Seattle, Washington
• University of Washington — Seattle, Washington
• Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Graft-versus-host-disease

• A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) — Duarte, California
• A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) — Birmingham, Alabama
• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Birmingham, Alabama

Explore by condition: All Chronic Graft-versus-host-disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.